View clinical trials related to Refractory Acute Leukemia.
Filter by:To find the recommended dose of hyper-CVAD in combination with dasatinib and venetoclax that can be given to participants with relapsed or refractory leukemia.
To find the highest safe dose of ziftomenib that can be combined with venetoclax and azacitidine in pediatric participants with acute leukemia that has certain types of genetic mutations (changes).